Abstract: A protective footwear includes a foot engagement portion, a lower-leg engagement portion, and a cable closure system. The lower-leg engagement portion defines a cable end interface and a buckle interface. The cable closure system is configured to facilitate at least partially securing the protective footwear to a leg of a wearer. The cable closure system includes a buckle assembly configured to releasably couple to the buckle interface and a cable extending between the cable end interface and the buckle assembly. The cable has a first end coupled to the cable end interface and an opposing second end coupled to the buckle assembly.

Abstract: A protective footwear includes a foot engagement portion, a lower-leg engagement portion, and a cable closure system. The lower-leg engagement portion defines a cable end interface and a buckle interface. The cable closure system is configured to facilitate at least partially securing the protective footwear to a leg of a wearer. The cable closure system includes a buckle assembly configured to releasably couple to the buckle interface and a cable extending between the cable end interface and the buckle assembly. The cable has a first end coupled to the cable end interface and an opposing second end coupled to the buckle assembly.

Abstract: A frame for an eyewear comprises a lens opening and a groove surrounding the lens opening. The lens opening may be defined by an upper frame portion, a lower frame portion, a first lateral side portion, and a second lateral side portion of the frame. The groove may interchangeably receive and secure a first lens and a second lens within the lens opening. The first lens may have a different thickness than the second lens. The lens opening may extend across both eyes of the wearer.

Abstract: A protective footwear includes a foot engagement portion, a lower-leg engagement portion, and a cable closure system. The lower-leg engagement portion defines a cable end interface and a buckle interface. The cable closure system is configured to facilitate at least partially securing the protective footwear to a leg of a wearer. The cable closure system includes a buckle assembly configured to releasably couple to the buckle interface and a cable extending between the cable end interface and the buckle assembly. The cable has a first end coupled to the cable end interface and an opposing second end coupled to the buckle assembly.

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and other types of transplantation. Inhibitors of IDO can be used to activate T cells. Inhibiting tryptophan degradation, or supplementing tryptophan concentration, can be used in addition to, or in place of, inhibitors of IDO. Increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. One can manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer tryptophan degrading enzymes.

Abstract: The present invention discloses pharmaceutical compositions containing 1-methyl-D-tryptophan and its utility to enhance rejection of tumor or virus-infected cells or to delay the progression of tumor growth. The present invention shows that pharmaceutical compositions containing 1-methyl-D-tryptophan enhance the efficacy of alternative antitumor or antiviral treatments such as chemotherapy, vaccination or cytokine therapy.

Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.

Abstract: The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.

Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.

Abstract: An adjustable vehicle support stand is provided that includes a base, a lower collar secured to the base, a rod, an upper collar and a plate secured to the upper collar. The plate is configured for attachment to a wheel hub of a vehicle. The rod includes a lower portion and an upper portion that are threadably engaged with the lower and upper collars, respectively. One of the lower and upper portions of the rod includes a plurality of left-hand external threads and the other of the lower and upper portions of the rod includes a plurality of right-hand external threads. The rod also includes a torquing portion that separates the lower and upper portions of the rod and that is configured to facilitate rotation of the rod. The plate is vertically movable relative to the base in response to rotation of the rod.

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Abstract: The induction of indoleamine 2,3-dioxygenase (IDO) in an IDO-competent subset of dendritic cells by TLR ligands, including TLR9 ligands, and various uses thereof are presented.

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Abstract: The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.

Abstract: The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor.

Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.